Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Mitomycin pyelocalyceal bulk supplier for pharma manufacturers

Mitomycin Pyelocalyceal 40 mg Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 40 mg

Reference Brands: Jelmyto (USA/EU)

Category: Oncology Cancer Care

Mitomycin pyelocalyceal is a formulation of mitomycin designed as a reverse-thermal hydrogel that becomes semi-solid at body temperature, allowing prolonged contact with the upper urinary tract. It is used for the treatment of low-grade upper tract urothelial cancer. The gel is instilled directly into the renal pelvis and calyces through a catheter and gradually dissolves to release the active drug.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

📘 Sourcing Guide

Mitomycin Pyelocalyceal — third party manufacturing & bulk supply

Mitomycin Pyelocalyceal 40 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

What to include when you enquire

  • Destination market — determines which manufacturers hold the right site-level approvals
  • First order quantity and estimated annual volume
  • Whether you need a registration dossier or the product is already registered
  • Packaging, labelling and language requirements
  • Incoterms and required shelf life

Manufacturers of Mitomycin Pyelocalyceal listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.

Request a quote for Mitomycin Pyelocalyceal →
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Frequently Asked Questions

Mitomycin pyelocalyceal solution is used to treat low-grade upper tract urothelial cancer (LG-UTUC) in the renal pelvis or calyces. It works by directly targeting cancer cells within the upper urinary tract.

It is made from mitomycin C formulated in a thermosensitive gel. The gel remains liquid during preparation and becomes semi-solid at body temperature, allowing it to stay in place within the pyelocalyceal system for sustained drug exposure.

The trade name is Jelmyto.

It is developed and manufactured by UroGen Pharma.

The generic name is Mitomycin for pyelocalyceal solution (mitomycin C).

The brand name is Jelmyto.

It is manufactured by UroGen Pharma in its regulated pharmaceutical production facilities and supplied to hospitals and clinics for administration through a catheter into the renal pelvis.

Related Products

Fruquin 5 Mg (Fruquintinib)

Strength:
5 Mg

Form: Capsules

Reference Brands: Everest Bangladesh altd.

View Details
Vorinostat

Strength:
100 mg

Form: Capsules

Reference Brands: Zolinza (USA/EU), Vornat (India)

View Details
Panobinostat Lactate

Strength:
10 mg, 15 mg, 20 mg

Form: Capsules

Reference Brands: Farydak (USA/EU),

View Details
Gilteritinib

Strength:
40 mg

Form: Tablets

Reference Brands: Xospata (USA/India), LuciGil (Asia)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.